Axel Grothey, MD
Dr. Axel Grothey is Professor of Oncology and Consultant in the Division of Medical Oncology in the Department of Oncology at the Mayo Clinic in Rochester, Minnesota. In addition, he is the Chairperson of Academic and Community Cancer Research United, a national network of academic and community cancer centers that is operationally based at Mayo Clinic. In this role, he oversees a clinical trial portfolio in various tumor entities and helps coordinate the Mayo Clinic Cancer Center’s research efforts within this network. Dr. Grothey’s primary areas of clinical interest are gastrointestinal malignancies, in particular, colorectal cancer, unknown primaries, and neuroendocrine tumors. As a clinical researcher, he is intricately involved in cancer studies conducted within the Mayo Clinic Cancer Center as a Principal Investigator or Co-Investigator.
Dr. Grothey is Vice Chairperson of the GI Committee of the Alliance for Clinical Trials in Oncology, as well as Chairperson of the National Cancer Institute’s Colon Task Force. He obtained a Doctor of Medicine degree from the Ruhr-University in Bochum, Germany. He completed a fellowship in hematology/oncology in Germany and a postdoctoral fellowship in Biochemistry and Molecular Biology at The University of Texas MD Anderson Cancer Center in Houston.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The presenting faculty members have all made the proper disclosures, and the following relationships are relevant:
Axel Grothey, MD, reported a financial interest/relationship or affiliation in the form of: Contracted research: Bayer Research Grant to Mayo/ Clinic Investigator; Eisai Research Grant to Mayo/Clinic Investigator; Eli Lilly Research Grant to Mayo/Clinic Investigator; Genentech Research Grant to Mayo/Clinic Investigator; Pfizer Research Grant to Mayo/Clinic Investigator.
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Linda Gracie-King, MS; Deborah Middleton, MS; and Jocelyn Timko, BS, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Johanna C. Bendell, MD
Dr. Johanna Bendell is Director of Gastrointestinal Oncology Research and Associate Director, Drug Development at Sarah Cannon Research Institute in Nashville, Tennessee. She leads gastrointestinal (GI) oncology research, designing trials across all GI tumor types, focusing on early drug development of primarily targeted agents. Dr. Bendell has published articles in multiple journals, including the Journal of Clinical Oncology, Cancer, and The Lancet.
Board certified in internal medicine and medical oncology, Dr. Bendell received a Doctor of Medicine degree from the University of Chicago. She completed an internship and residency in the Department of Internal Medicine at Brigham and Women’s Hospital in Boston, Massachusetts, as well as a fellowship in adult oncology at Dana-Farber Cancer Institute.
Johanna C. Bendell, MD, has no real or apparent conflicts of interest to report.
Al B. Benson, III, MD, FACP
Dr. Al B. Benson III is a Professor of Medicine in the Division of Hematology/Oncology at Northwestern University’s Feinberg School of Medicine in Chicago, Illinois. He is also the Associate Director for Clinical Investigations at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, an Attending Physician at Northwestern Memorial Hospital, a Staff Physician at Jesse Brown VA Medical Center, and a Consultant to the Rehabilitation Institute of Chicago. Dr. Benson’s research is primarily in the areas of gastrointestinal cancer clinical trials, cancer clinical trials, biologic therapies, phase 1 cancer clinical trials, and cancer guideline development. He has authored and coauthored numerous reports, reviews, and book chapters focusing on these topics. His research in biologics, cancer therapy, and cancer prevention has been awarded funding from a variety of sources including the National Institutes of Health.
Dr. Benson is active on numerous professional committees. He is Chairperson of the Data Monitoring Committee and a member of the National Cancer Institute’s Rectal/Anal Cancers and the Colon Cancer Task Forces. He is also Chairperson of the International Rare Cancers Initiative, Anal Cancers Committee, and a member of the Small Intestinal Cancer Committee. He is Chairperson of both panels of the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for hepatobiliary cancer and colon, rectal and anal cancer, and a panel member for pancreatic cancer and neuroendocrine cancer panels. Dr. Benson is a member of the executive committee of the Patient Advocate Foundation, the National Patient Advocate. Dr. Benson is on the editorial board of the American Society of Clinical Oncology Connection, Journal of the National Comprehensive Cancer Network, American Health and Drug Benefits Personalized Medicine in Oncology, Journal of Comparative Effectiveness Research, and Gastrointestinal Cancer Research, among others. His most recent national awards include the NCCN® Rodger J. Winn award and the Association of Community Cancer Centers Outstanding Achievement in Clinical Research Award.
Dr. Benson earned a Doctor of Medicine degree at the State University of New York at Buffalo, following which he completed a residency in internal medicine at the University of Wisconsin Hospitals in Madison, Wisconsin.
Al B. Benson III, MD, FACP, FASCO, reported a financial interest/relationship or affiliation in the form of: Consulting fee: Amgen, Inc.; Bayer Pharmaceuticals Corporation; Bristol-Myers Squibb Company; Genentech, Inc.; IntraGen; Lilly/ImClone; sanofi US; Contracted research paid to Northwester University: Amgen, Inc.; Astellas Pharma US, Inc.; AVEO Pharmaceuticals, Inc.; Genentech, Inc.; Gilead; Novartis Pharmaceuticals Corporation.
Barbara A. Burtness, MD
Dr. Barbara A. Burtness joined medical oncology at Yale Cancer Center, and serves as Co-Leader of the Developmental Therapeutics Program and Director of the Clinical Research Program for Head and Neck Cancer. Dr. Burtness is internationally recognized for her research in head and neck cancer. She chairs the Eastern Cooperative Oncology Group Head and Neck Cancer Committee, and leads national and international trials of targeted therapy in head and neck cancer. Dr. Burtness is Principal Investigator of a phase 1 clinical trial of cetuximab with escalating doses of the mechanistic target of rapamycin inhibitor everolimus to target signaling from pAkt, and an investigator-initiated phase 2 trial of chemotherapy plus cetuximab, followed by addition of erlotinib.
Dr. Burtness has served as peer reviewer for numerous publications and is on the editorial boards for Clinical Colorectal Cancer, Cancer Investigation, HemOnc Today, Frontiers in Oncology, Journal of Clinical Oncology, and Clinical Cancer Research. She received a Doctor of Medicine degree from State University of New York at Stony Brook.
Barbara A. Burtness, MD, reported a financial interest/relationship or affiliation in the form of: Consulting fee: Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; VentiRX Pharmaceuticals; Contracted research: Boehringer Ingelheim Grant to Fox Chase: Genentech Grant to Fox Chase; Other: Johnson & Johnson Expert Witness.
Cathy Eng, MD, FACP
Cathy Eng, MD, FACP, has served on the Gastrointestinal Medical Oncology faculty at MD Anderson Cancer Center (MDACC) in Houston, Texas, for many years, assuming increasingly responsible leadership positions devoted to clinical research in colorectal, appendiceal, and anal cancer while also promoting the prevention of colorectal cancer in the community by co-founding and co-chairing the annual Sprint for Colorectal Oncology Prevention and Education. Serving as a strong advocate for the conduct of research within cooperative groups, Dr. Eng became the MDACC Principal Investigator of the National Cancer Institute (NCI) Southwest Oncology Group (SWOG) U10 grant focused on early phase 2 to 3 clinical trials. Dr. Eng is now serving as the lead contact Principal Investigator for the multidisciplinary NCI National Clinical Trials Network Lead Academic Participating Sites U10 grant, which will serve as an umbrella grant to provide scientifi and administrative leadership in the conduct of cancer research within all of MDACC’s clinical cooperative groups.
Dr. Eng has been very active on American Society of Clinical Oncology (ASCO) committees—recently as Chairperson of the Scientific Program Committee of the ASCO Gastrointestinal Cancer Symposium from 2012 to 2013 and has been a member of its Steering Committee 2012 continuing through 2015. She also served on ASCO’s Career Development Committee from 2004 to 2007 and Education Committee for Colorectal Cancer from 2007 to 2008. Dr. Eng co-chaired the ASCO annual meeting gastrointestinal-colorectal oral presentations session in 2007 and served as the ASCO Scientific Program Committee Track Leader for the Gastrointestinal Cancer-Colorectal/Liver Track 2006-2008. She was chosen for the ASCO Leadership Development Program, class of 2012. Dr. Eng is currently serving on the ASCO Government Relations Committee.
Dr. Eng received a Doctor of Medicine degree from Hahnemann University School of Medicine in Philadelphia, Pennsylvania. She also completed a residency in PGY-2 Diagnostic Radiology at St. Barnabas Medical Center in Livingston, New Jersey, and a residency in internal medicine at Rush-Presbyterian St. Luke’s Medical Center in Chicago, Illinois.
Cathy Eng, MD, FACP, reported a financial interest/relationship or affiliation in the form of Consulting fee: Bayer Pharmaceuticals Corporation; Genentech, Inc.; Roche USA; Contracted research: Amgen, Inc.; Keryx Biopharmaceuticals, Inc.
Daniel G. Haller, MD, FACP, FASCO, FRCP
Daniel G. Haller, MD, FACP, FASCO, FRCP, has been the Deenie Greitzer Gastrointestinal Medical Oncology Professor Emeritus at the University of Pennsylvania (Penn) since 2009. He is also Attending Physician at the Hospital of the University of Pennsylvania. He received the John Glick Teaching Award and the Clinical Specialist Award of the Year from Penn. His chief areas of clinical research are in the management of gastrointestinal malignancies.
Dr. Haller is currently Co-Chair Emeritus of the National Cancer Institute’s Gastrointestinal Intergroup. He is a Fellow of the American Society of Clinical Oncology (ASCO), and has chaired the program and the audit and finance committees. He was given the Distinguished Achievement Award from ASCO. Dr. Haller is an active member of the American Association for Cancer Research and the European Society for Medical Oncology. In 2013, he was elected a Fellow of the Royal College of Physicians.
Dr. Haller is the author and coauthor of more than 150 peer-reviewed publications and is Co-Editor of the 3rd edition of the Oxford Textbook of Oncology (in press), Editor-in-Chief of ASCO University, and Editor of Gastrointestinal Cancer Research. He received a Doctor of Medicine degree from the University of Pittsburgh in Pennsylvania and completed residency and oncology training at Georgetown University in Washington, DC.
Daniel G. Haller, MD, FACP, FASCO, FRCP, reported a financial interest/relationship or affiliation in the form of: Consulting fee: Genentech, Inc.; Speakers' bureau: Celgene Corporation.
J. Randolph Hecht, MD
J. Randolph Hecht, MD, is Professor of Clinical Medicine and the Carol and Saul Rosenzweig Chair for Cancer Therapies Development at the University of California, Los Angeles (UCLA). He is the Director of the UCLA Gastrointestinal (GI) Oncology Program, one of the largest such programs in the West. His clinical and research interests are exclusively in the treatment of cancers of the GI tract. Based on translational research from the UCLA translational oncology research laboratories, Dr. Hecht has developed and led trials on gene therapies, antiangiogenic drugs, growth factor inhibitors, and other novel agents in esophageal, gastric, pancreatic, and colorectal cancers. This includes leading and publishing the results of multiple large randomized studies with small molecule anti–vascular endothelial growth factor-2 tyrosine kinase inhibitors and anti–epidermal growth factor receptor inhibitors in colorectal cancer. Dr. Hecht is currently the Global Principal Investigator on an international randomized phase 2 trial for patients with second-line metastatic colorectal cancer using an antibody to LOXL2. Dr. Hecht is also on the medical advisory board and has spoken for the national colorectal cancer advocacy group Chris4Life. He received a Doctor of Medicine degree from Eastern Virginia Medical School in Norfolk, Virginia.
J. Randolph Hecht, MD, reported a financial interest/relationship or affiliation in the form of: Consulting fee: Genentech - A member of the Roche Group.
Joleen M. Hubbard, MD
Dr. Joleen Hubbard is Assistant Professor of Medical Oncology at Mayo Clinic in Rochester, Minnesota. She specializes in the treatment of gastrointestinal cancers, focusing on colorectal cancer, which is also her primary area of interest in clinical research. Her additional research interests include geriatric oncology with a special interest in clinical and biologic markers of frailty.
Dr. Hubbard is the Principal Investigator of several phase 1 clinical trials investigating novel agents for gastrointestinal cancers. She is also Chairperson of the Gastrointestinal Tumor Group Practice at Mayo Clinic and serves as a member of the Cancer in the Elderly and the Health Reported Outcomes and Translational Research committees for the North American Alliance of Clinical Trials in Oncology Network. Dr. Hubbard received a Doctor of Medicine degree and completed a residency at the University of Minnesota in Minneapolis.
Joleen M. Hubbard, MD, reported a financial interest/relationship or affiliation in the form of: Advisory board: Bayer Pharmaceuticals Corporation; Contracted research: Boston Biomedical; Genentech, Inc.; Prism Pharmaceuticals, Inc.
David H. Ilson, MD, PhD
David H. Ilson is Attending Physician at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill-Cornell Medical College in New York, New York. A nationally recognized authority in the treatment of gastrointestinal cancer, his area of research interest is upper gastrointestinal cancer with a focus on esophageal cancer. Dr. Ilson’s research has focused on the study of new agents in advanced esophageal cancer, and the evaluation of novel agents in combined modality therapy programs in locally advanced disease. He is a member of the gastrointestinal (GI) committees of Cancer and Leukemia Group B (CALGB) and Radiation Therapy Oncology Group (RTOG), and the Upper GI Cancer Guidelines Committee of the National Comprehensive Cancer Network®. Dr. Ilson is currently Chairperson and Co-Chairperson of several national clinical trials in esophageal cancer, including RTOG 0436 and CALGB 80803.
Dr. Ilson received a Doctor of Medicine degree from New York University and completed his internship and residency in internal medicine at Bellevue Hospital at New York University in New York, New York.
David H. Ilson, MD, PhD, has no real or apparent conflicts of interest to report.
Nancy E. Kemeny, MD
Nancy E. Kemeny, MD, is a Medical Oncologist at Memorial Sloan Kettering Cancer Center (MSKCC) and Professor of Medicine at the Weill Medical College of Cornell University in New York, New York. During her 30 years at MSKCC, she conducted some of the fi t studies using drugs such as irinotecan and oxaliplatin, which are now widely used in patients with colorectal cancer. Dr. Kemeny also was the lead investigator of a large, multi- institutional study that facilitated the US Food and Drug Administration approval of oxaliplatin for colorectal cancer treatment. Her research has included numerous studies of regional therapy to improve outcomes in patients with this malignancy.
Dr. Kemeny is active in oncology issues on a national level, including having held various positions at the American Society of Clinical Oncology and membership on the Carcinoembryonic Antigen Tumor Marker Panel. In addition, Dr. Kemeny was Principal Investigator of a National CALGB protocol evaluating regional liver therapy versus systemic therapy in patients whose disease spread from the colon to the liver. She is a Scientific Reviewer for many journals and serves on the editorial board of three journals. Dr. Kemeny received a Doctor of Medicine degree from the University of Medicine & Dentistry of New Jersey in Newark, New Jersey.
Nancy E. Kemeny, MD, has no real or apparent conflicts of interest to report.
Heinz-Josef Lenz, MD, FACP
Dr. Heinz-Josef Lenz is Professor of Medicine and Preventive Medicine, holds the Kathryn Balakrishnan Chair for Cancer Research, is Associate Director of Clinical Research, is Co-Chair of GI Oncology, and is Co-Director of the University of Southern California (USC) Center for Molecular Pathways and Drug Discovery at the USC Keck School of Medicine and USC/ Norris Comprehensive Cancer Center in Los Angeles, California. His research focus is on the identification of biomarkers in gastrointestinal (GI) cancers, early drug development, and novel clinical trials. He is Co-Chairperson of the Southwest Oncology Group (SWOG) GI Committee and Co-Chairperson of SWOG GI Translational Medicine. Dr. Lenz is also a member of the National Cancer Institute (NCI) GI Steering Committee, NCI Gastroesophageal Task Force, and NCI Correlative Science Committee. He is the USC Principal Investigator for National Institutes of Health U01, N01, and U10.
Dr. Lenz received a Doctor of Medicine degree from Johannes-Gutenberg Universität in Mainz, Germany, and completed a residency in hematology and oncology at the Eberhard-Karls Universität Tübingen, Germany, before completing clerkships in oncology and hematology at George Washington University in Washington, DC, and the Beth Israel Hospital of Harvard Medical School in Boston, Massachusetts. He completed a postdoctoral fellowship in the Department of Biochemistry and Molecular Biology at the USC Keck School of Medicine.
Heinz-Josef Lenz, MD, reported a financial interest/relationship or affiliation in the form of: Consulting fee: Bayer Pharmaceuticals Corporation; Bristol-Myers Squibb Company; Merck/EMD serono; Roche USA; Contracted research: Bayer Pharmaceuticals Corporation; Boehringer Ingelheim; Bristol-Myers Squibb Company; EMD Serono, Inc.; Pfizer, Inc.; Roche USA.
Christopher Lieu, MD
Christopher Lieu, MD, joined the University of Colorado School of Medicine faculty as an Assistant Professor in July 2011. He trained in internal medicine at the University of Colorado, where he also served as a Chief Medical Resident. He completed his fellowship training in medical oncology at the University of Texas MD Anderson Cancer Center in Houston, where he also served as the Chief Medical Oncology Fellow in 2010.
Dr. Lieu’s clinical interests include resistance mechanisms to targeted therapy in gastrointestinal cancers, and in 2013, he received the Conquer Cancer Foundation Career Development Award to study targeted therapies in colorectal cancer. He is a member of the Developmental Therapeutics (phase 1 clinical trials) and Gastrointestinal Medical Oncology Program—comprehensive programs that include multidisciplinary cancer clinics, tumor boards, and research endeavors. Dr. Lieu received a Doctor of Medicine degree from Wake Forest University School of Medicine in Winston-Salem, North Carolina.
Christopher Lieu, MD, has no real or apparent conflicts of interest to report.